



AF/1623
IJW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of
Mary, et al

Application No.: **09/752,926**

Filed: **January 2, 2001**

Title: **Novel Therapeutic Application of
Enoxaprin**

Examiner: **Leigh Maier**

Art Unit: **1623**

CERTIFICATE OF TRANSMISSION
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 18, 2004
Date of Deposit

Bonnie Stein
Signature

**EXPRESS ABANDONMENT AND REQUEST FOR WITHDRAWAL
OF APPEAL**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Honorable Commissioner of Patents:

The above-identified parent application is currently on appeal. A Request for Oral Hearing was filed on March 8, 2004 via facsimile.

A continuation application, U.S. Serial No. 10/849,356 was filed on May 19, 2004.

Applicants hereby abandon said parent application No. 09/752,926 and withdraw the pending appeal. They will continue prosecution of the subject matter of Application 09/752,926 in the above-identified continuation application (U.S. Serial No. 10/849,356).

Respectfully submitted,


Irving Newman, Reg. No. 22,638
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2785
Telefax (908) 231-2626

Aventis Docket No. USST00001US NP